Scilex Holding Co (SCLX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Scilex reported revenue of $30.3M, down 46.5% from $56.6M the year before. Net income was -$374.1M (a -1236.4% net margin), or -$36.48 per diluted share. Gross margin was 415.8% and operating margin was -1143.7%. Operating activities generated $3.8M of cash, leaving $3.7M of free cash flow. At fiscal year end, Scilex held $365.0M in total assets against $576.7M in total liabilities, including $5.0M of cash and equivalents.
Open the full interactive Scilex financials → Quarterly statements, key ratios, valuation history and price charts.
Scilex Key Stats
| Share Price | $2.88 |
|---|---|
| Market Cap | $19.8M |
| Revenue YoY Growth | -46.5% |
| 52-Week Range | $2.80 – $14.02 |
| Shares Outstanding | 6.9 million (basic, 2026 Q2) |
Scilex Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $38.0M | $46.7M | $56.6M | $30.3M |
| Cost of Goods Sold | $0 | — | — | — | $96.3M |
| Gross Profit | $0 | $27.2M | $31.1M | $39.9M | $125.8M |
| Operating Income | -$1.0M | -$50.6M | -$105.4M | -$83.4M | -$346.0M |
| Pre-Tax Income | $783,438 | -$23.4M | -$114.3M | -$72.8M | -$374.0M |
| Income Tax | — | $4,000 | $13,000 | -$1,000 | $26,000 |
| Net Income | $783,438 | -$23.4M | -$114.3M | -$72.8M | -$374.1M |
| Diluted EPS | $1.75 | -$5.95 | -$44.80 | -$21.35 | -$36.48 |
Scilex Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $10.6M | $4.8M | $8.6M | $7.6M |
| Net Income | -$257.8M | -$46.1M | -$45.6M | -$115.0M |
| Diluted EPS | -$22.17 | -$4.18 | -$6.28 | -$16.65 |
Scilex Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $507,921 | $2.2M | $3.9M | $3.3M | $5.0M |
| Current Assets | $512,457 | $29.6M | $46.8M | $41.5M | $38.4M |
| Total Assets | $139.9M | $86.5M | $101.3M | $93.0M | $365.0M |
| Current Liabilities | $208,704 | $44.8M | $250.4M | $259.6M | $483.7M |
| Total Long-Term Debt | $483,099 | — | $121.1M | $13.0M | $50.2M |
| Total Liabilities | $9.2M | $50.3M | $274.2M | $285.6M | $576.7M |
| Shareholders' Equity | -$8.7M | $36.2M | -$172.9M | -$192.6M | -$207.8M |
Scilex Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$801,330 | -$21.3M | -$20.7M | $19.3M | $3.8M |
| Cash From Investing | -$139.4M | -$2.1M | -$330,000 | -$2.7M | $4.1M |
| Cash From Financing | $140.7M | $21.2M | $23.6M | -$18.1M | -$5.5M |
| Free Cash Flow | — | $21.3M | $20.7M | $19.3M | $3.7M |
| Dividends Paid | — | — | $8.7M | $8.7M | — |
Figures from Scilex's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Scilex financials page for every line item.
Scilex Company Profile
| Ticker | SCLX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Palo Alto, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001820190 |
Frequently Asked Questions
What was Scilex's revenue in fiscal 2025?
Scilex (SCLX) reported revenue of $30.3M for fiscal 2025.
What is Scilex's annual revenue history?
Scilex's annual revenue by fiscal year: 2021: $0; 2022: $38.0M; 2023: $46.7M; 2024: $56.6M; 2025: $30.3M.
What was Scilex's net income in fiscal 2025?
Scilex reported net income of -$374.1M for fiscal 2025.
What was Scilex's earnings per share (EPS) in fiscal 2025?
Scilex's diluted EPS was -$36.48 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Scilex generate in fiscal 2025?
Scilex generated $3.7M of free cash flow in fiscal 2025.
What was Scilex's revenue last quarter?
In its most recent reported quarter (2026 Q2), Scilex reported revenue of $7.6M.
How much debt does Scilex have?
Scilex reported $50.2M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Scilex are outstanding?
Scilex reported a weighted average of 6.9 million basic shares outstanding in 2026 Q2.
What is Scilex's market cap?
Based on its latest closing price, Scilex (SCLX) has a market capitalization of about $19.8M.
When does Scilex's fiscal year end?
Scilex's fiscal year end, as registered with the SEC, is December 31.
Where is Scilex headquartered?
Scilex lists its business address in Palo Alto, California in its SEC filings.
Scilex Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →